



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/705, A61K 38/17, A61P 37/02, G01N 33/569, 33/68</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/32632</b> <b>(43) International Publication Date:</b> 8 June 2000 (08.06.00)
<b>(21) International Application Number:</b> PCT/GB99/04027 <b>(22) International Filing Date:</b> 1 December 1999 (01.12.99)  <b>(30) Priority Data:</b> 9826378.3 1 December 1998 (01.12.98) GB  <b>(71) Applicants (for all designated States except US):</b> ABERDEEN UNIVERSITY [GB/GB]; Auris University Centre, 23 St. Machar Drive, Aberdeen AB2 1RY (GB). THE COMMON SERVICES AGENCY FOR THE SCOTTISH HEALTH SERVICE [GB/GB]; Trinity Party House, South Trinity Road, Edinburgh EH5 3SE (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> URBANIAK, Stanislaw, Joseph [GB/GB]; 14 Earlsparck Crescent, Bieldside, Aberdeen AB15 9AY (GB). BARKER, Robert, Norman [GB/GB]; Courtin, Barthol Chapel, Inverurie AB51 8TD (GB).  <b>(74) Agents:</b> ABLETT, Graham, Keith et al.; Ablett & Stebbing, Caparo House, 101-103 Baker Street, London W1M 1FD (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> ALLO AND AUTO-REACTIVE T-CELL EPITOPES		
<b>(57) Abstract</b>  The present invention relates to a pharmaceutical composition for the prevention of alloimmunisation of a subject or the immunosuppression of a response elicited by alloimmunisation of a subject or an autoimmune haemolytic disease for said composition comprising an immunologically effective epitope of a rhesus protein or an immunologically active analogue or derivative thereof.		